Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine Targets.
Publication
, Journal Article
Crosby, EJ; Hartman, ZC; Lyerly, HK
Published in: Clin Cancer Res
September 1, 2023
A vaccine targeting HER2, a nonmutated but overexpressed tumor antigen, readily primed T cells for ex vivo expansion and adoptive transfer with minimal toxicity. This regimen led to intramolecular epitope spreading in a majority of patients and offers a treatment modality that may improve outcomes for patients with metastatic breast cancer expressing HER2. See related article by Disis et al., p. 3362.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Clin Cancer Res
DOI
EISSN
1557-3265
Publication Date
September 1, 2023
Volume
29
Issue
17
Start / End Page
3256 / 3258
Location
United States
Related Subject Headings
- T-Lymphocytes
- Receptor, erbB-2
- Receptor, ErbB-2
- Oncology & Carcinogenesis
- Humans
- Female
- Cancer Vaccines
- Breast Neoplasms
- Antigens, Neoplasm
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Crosby, E. J., Hartman, Z. C., & Lyerly, H. K. (2023). Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine Targets. Clin Cancer Res, 29(17), 3256–3258. https://doi.org/10.1158/1078-0432.CCR-23-1244
Crosby, Erika J., Zachary C. Hartman, and H Kim Lyerly. “Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine Targets.” Clin Cancer Res 29, no. 17 (September 1, 2023): 3256–58. https://doi.org/10.1158/1078-0432.CCR-23-1244.
Crosby EJ, Hartman ZC, Lyerly HK. Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine Targets. Clin Cancer Res. 2023 Sep 1;29(17):3256–8.
Crosby, Erika J., et al. “Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine Targets.” Clin Cancer Res, vol. 29, no. 17, Sept. 2023, pp. 3256–58. Pubmed, doi:10.1158/1078-0432.CCR-23-1244.
Crosby EJ, Hartman ZC, Lyerly HK. Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine Targets. Clin Cancer Res. 2023 Sep 1;29(17):3256–3258.
Published In
Clin Cancer Res
DOI
EISSN
1557-3265
Publication Date
September 1, 2023
Volume
29
Issue
17
Start / End Page
3256 / 3258
Location
United States
Related Subject Headings
- T-Lymphocytes
- Receptor, erbB-2
- Receptor, ErbB-2
- Oncology & Carcinogenesis
- Humans
- Female
- Cancer Vaccines
- Breast Neoplasms
- Antigens, Neoplasm
- 3211 Oncology and carcinogenesis